Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity . Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

What It's Researched For

In plain terms, IGF-DES is IGF-1 with the handle broken off that its carrier proteins normally grab. Here is why researchers use it.

Local, not systemic

It acts strongly where it is applied and clears fast, which is exactly what you want when studying a tissue rather than a whole organism.

Isolating the receptor

Because the binding proteins barely hold it, effects can be attributed to the IGF-1 receptor rather than to changes in availability.

Muscle and satellite cells

Used in muscle research to probe the IGF-1 pathway’s role in satellite-cell activation and tissue growth.

Potency benchmarking

A standard comparator for measuring how much of IGF-1’s apparent activity is really binding-protein regulation.

Overview

In short: IGF-DES is DES(1-3)IGF-1: insulin-like growth factor 1 missing its first three residues, which strips away most binding-protein control and converts a long-acting systemic hormone into a short, locally potent signal.

Key research facts

Truncated IGF-1 analogue missing the N-terminal Gly-Pro-Glu tripeptide (67 residues)

Roughly 100-fold lower affinity for the IGF binding proteins than intact IGF-1

Reported several-fold greater potency than IGF-1 in cell and tissue models

Short circulating persistence — the binding proteins that prolong IGF-1 no longer retain it

Signals through the same IGF-1 receptor and downstream PI3K/Akt and MAPK pathways

Research use only. These points summarise lab themes, not human outcomes.

Insulin-like growth factor 1 is a 70-amino-acid protein that mediates much of growth hormone’s anabolic effect. In circulation it is almost never free: more than 95% is captured by a family of six insulin-like growth factor binding proteins, which extend its half-life dramatically while simultaneously keeping it away from its receptor. Availability, not absolute concentration, is what the IGFBP system regulates.

IGF-DES removes the part of the molecule that system grips. Deleting the N-terminal glycine-proline-glutamate tripeptide leaves a 67-residue protein whose affinity for the binding proteins falls by roughly a hundredfold. The consequences run in both directions at once. Free growth factor reaches the IGF-1 receptor readily, so reported potency in cell and tissue models is several-fold higher than intact IGF-1 at matched concentrations. But the same binding proteins are what kept IGF-1 in circulation for hours, so without them the truncated form is cleared quickly — its persistence is measured in tens of minutes.

That trade-off is precisely why the molecule is useful in research. It lets an experiment separate two things that are normally confounded: how strongly the IGF-1 receptor responds, and how much growth factor the binding proteins allow through. DES(1-3)IGF-1 is not an exotic synthetic construct either — it occurs naturally in bovine colostrum and has been identified in human brain tissue. It is supplied here as a research-grade lyophilised powder for in-vitro and preclinical use only, and nothing on this page is medical advice.

Mechanism of Action

IGF-DES binds the IGF-1 receptor and triggers the same PI3K/Akt and MAPK cascades as intact IGF-1, but because the deleted N-terminal tripeptide is the main IGFBP contact site, it circulates largely unbound — more receptor engagement, much shorter duration.

Pathway Effect Why it matters IGFBP evasion Loss of the N-terminal Gly-Pro-Glu drops binding-protein affinity roughly 100-fold The single change from which every other property follows IGF-1 receptor activation Binds and autophosphorylates the IGF-1R tyrosine kinase The shared entry point for all IGF-1 signalling PI3K / Akt / mTOR Drives the principal anabolic and pro-survival arm downstream of the receptor Protein synthesis and apoptosis suppression in the research literature MAPK / ERK Activates the proliferative arm of receptor signalling Cell-cycle entry and proliferation endpoints Rapid clearance Without binding-protein reservoir capacity, plasma persistence collapses Confines the effect locally — the defining practical property

Deeper dive for scientific readers

The IGFBP system is best understood as a buffer with a brake built in. It holds a large reservoir of growth factor, protects it from clearance, and releases it under proteolytic control — which is why intact IGF-1 has a half-life measured in hours despite the receptor being ubiquitous. The N-terminal residues of IGF-1 sit in the binding interface, so removing them does not alter receptor recognition appreciably but does dismantle the buffer. Reported potency gains of roughly three- to tenfold in cell systems are therefore best read as a availability effect rather than as evidence that the truncated protein is intrinsically a better agonist. Two practical consequences follow for experimental design. First, dose-matching by mass against intact IGF-1 will overshoot, and the literature does not treat the two as interchangeable. Second, because IGFBP expression varies substantially between cell types and culture conditions, the potency ratio between IGF-DES and IGF-1 is itself a readout of how much binding protein a given system produces — which is exactly the comparison that makes the molecule a useful tool.

Common Questions People Are Asking

What is IGF-DES used for in research?

It is used as a tool for studying IGF-1 receptor signalling without the confounding influence of the binding-protein system — commonly in muscle and satellite-cell work, and in potency-benchmarking experiments run alongside intact IGF-1. It is supplied here for laboratory research only and is not for human use.

How does IGF-DES differ from IGF-1 LR3?

Both are IGF-1 analogues engineered to evade the binding proteins, but by opposite means. IGF-DES removes the N-terminal tripeptide, giving very low IGFBP affinity and a very short half-life. IGF-1 LR3 substitutes Arg at position 3 and adds a 13-residue N-terminal extension, which also reduces IGFBP binding but produces a much longer-lived molecule. Short and local versus long and systemic.

Why is IGF-DES described as more potent than IGF-1?

Mostly because more of it is free. Intact IGF-1 is over 95% bound in circulation, so only a small fraction reaches the receptor at any moment; IGF-DES largely escapes that capture. The reported several-fold potency advantage is therefore better read as an availability effect than as evidence the truncated protein is intrinsically a stronger agonist at the receptor.

Is IGF-DES a synthetic molecule?

Not exclusively. DES(1-3)IGF-1 occurs naturally — it has been identified in bovine colostrum and in human brain tissue. The research-grade material supplied here is produced synthetically, but the molecule itself is a natural truncation product of IGF-1.

How should IGF-DES be reconstituted and stored?

Keep the lyophilised powder frozen at −20 °C, protected from light and moisture. Protocols commonly use dilute acetic acid water for the initial dissolution because the protein is poorly soluble at neutral pH, then dilute with bacteriostatic water. Refrigerate the solution at 1–6 °C, aliquot it, and avoid repeated freeze-thaw cycles — as a small protein it also adsorbs to container surfaces, so low-binding tubes are common in the literature.

Where can I buy IGF-DES?

Right here — IGF-DES is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.

How much does IGF-DES cost?

IGF-DES pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.

Is IGF-DES third-party tested?

Yes. Every IGF-DES batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.

How do I buy IGF-DES?

Add the IGF-DES pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). IGF-DES is supplied strictly for laboratory research use only, not for human or veterinary use.

What payment methods can I use to buy IGF-DES?

At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.

Is it legal to buy IGF-DES?

In the United States, IGF-DES is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Pharmacokinetics

Half-life Short — reported on the order of tens of minutes, against several hours for binding-protein-bound intact IGF-1 Absorption route Administered parenterally in published animal work; not orally bioavailable as a protein Bioavailability Effectively unbound in circulation, in contrast to intact IGF-1 where over 95% is IGFBP-associated Metabolism / clearance Cleared by the usual proteolytic routes without the protective reservoir the IGFBPs normally provide Stability Lyophilised powder stable frozen; in solution susceptible to surface adsorption and freeze-thaw losses Notes These are descriptions of published experimental behaviour, not guidance for use.

Evidence Tier

Overall: Tier 2: Animal / preclinical

DES(1-3)IGF-1 is a well-characterised research protein with a substantial in-vitro and animal literature going back to the 1980s, including the structural work establishing the N-terminal IGFBP interaction and comparative potency studies against intact IGF-1. Its naturally occurring status in bovine colostrum and human brain tissue is established. What does not exist is a controlled human therapeutic literature: it is used as a laboratory tool compound, not an approved drug, and it has no regulatory approval in any jurisdiction.

Tier 2 · Animal

Comparative potency and IGFBP-affinity studies in cell culture and animal models are long-established; no controlled human trial of DES(1-3)IGF-1 is cited on this page

Certificates, databases & peer-reviewed sources

Last reviewed: 6 August 2026 · New-U Research Compounds

PubMed: peer-reviewed literature on IGF-DES

ClinicalTrials.gov: registered studies on IGF-DES

IGF-DES: Wikipedia

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

DES(1-3)IGF-1 — IGF-1 lacking the N-terminal Gly-Pro-Glu tripeptide

67 amino acids, approximately 7,371 Da

Roughly 100-fold reduced affinity for the IGF binding proteins

Reported several-fold higher potency than intact IGF-1 in cell models

Markedly shorter persistence — tens of minutes, not hours

Signals through the IGF-1 receptor via PI3K/Akt and MAPK

Occurs naturally in bovine colostrum and human brain tissue

Research-grade purity: >98% HPLC — confirm against the supplied batch certificate

Specifications

Full Name DES(1-3) insulin-like growth factor 1 Length 67 amino acids (IGF-1 minus Gly-Pro-Glu) Molecular Weight ≈7,371 Da Class Truncated growth-factor protein Purity >98% (HPLC) Form Lyophilised powder IGFBP Affinity Approximately 100-fold lower than intact IGF-1 Solubility Acetic acid water for initial dissolution; bacteriostatic water thereafter Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C; aliquot, avoid freeze-thaw.

About IGF-DES: DES(1-3)IGF-1 Truncated Growth Factor Research Guide

Insulin-like growth factor 1 does not act alone. In the bloodstream it is almost entirely bound to a family of six binding proteins, which protect it from clearance and, in doing so, keep it away from its receptor until it is released. That system is the real regulator of IGF-1 activity: the amount of hormone present matters far less than the fraction the binding proteins let go. Understanding IGF-DES means understanding that this is the system it circumvents.

IGF-DES — DES(1-3)IGF-1 — is IGF-1 with its first three residues, glycine-proline-glutamate, removed. Those residues sit in the binding-protein interface, so their loss cuts IGFBP affinity by roughly a hundredfold while leaving receptor recognition largely intact. Two things follow at once. The truncated protein reaches the IGF-1 receptor much more readily and is reported to be several-fold more potent than intact IGF-1 in cell and tissue models. And it disappears quickly, because the same binding proteins were what gave IGF-1 its long half-life. Strong, local, brief — that is the profile.

For research that trade-off is the point rather than a limitation. Running IGF-DES alongside intact IGF-1 in the same system separates two normally confounded variables: how responsive the receptor is, and how much growth factor the binding proteins permit through. It is also a naturally occurring molecule, identified in bovine colostrum and in human brain tissue, rather than a purely synthetic construct. New-U Research Compounds supplies IGF-DES as a research-grade lyophilised powder at >98% HPLC purity, strictly for in-vitro and preclinical research use. It is not approved for human therapeutic use in any jurisdiction, and nothing on this page constitutes medical advice or a dosing recommendation.

Insulin-like growth factor 1 - Wikipedia

Insulin-like growth factor-binding protein - Wikipedia

Insulin-like growth factor 1 receptor - Wikipedia

PI3K/AKT/mTOR pathway - Wikipedia

Customer Reviews

No customer reviews yet — be the first to share your experience.

More in Muscle / Performance

IGF-1 LR3

PEG-MGF

IGF-DES vs related Muscle / Performance compounds

Compound Price Purity spec COA IGF-DES from $139 >98% HPLC On request IGF-1 LR3 from $99 >99% HPLC On request PEG-MGF from $159 >99% HPLC On request

Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.

More on IGF-DES

IGF-DES research guide

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.